文献速递心脏核医学

疑似与确诊转甲状腺素蛋白淀粉样变性心肌病且左心室功能保留患者中[99mTc]Tc-DPD定量SPECT/CT的预后价值

Prognostic Value of [99mTc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function.
PubMed 文献 · J Nucl Med · 2024-06-03

本研究纳入144例疑似转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)患者,按基线左心室射血分数(LVEF)≥50%与<50%分组,分析[99mTc]Tc-DPD定量SPECT/CT的SUVmax与SUVpeak对主要不良心脏事件的预测价值。在疑似或确诊ATTR-CM且LVEF≥50%的患者中,心肌SUVmax至少7可预测随访21.9±13.0个月内的主要不良心脏事件(HR 2.875;95%CI 1.23-6.71;P=0.015);在LVEF<50%的患者中SUVmax无预测价值。作者认为对LVEF保留的早期阶段患者应考虑定量SPECT以改善早期风险分层。

要点

  • 疑似或确诊ATTR-CM且LVEF≥50%患者中,心肌SUVmax至少7与主要不良心脏事件相关(HR 2.875;95%CI 1.23-6.71;P=0.015)。
  • LVEF<50%的疑似或确诊ATTR-CM患者中,SUVmax未显示预测价值。
  • 作者认为对LVEF保留的早期ATTR-CM患者应考虑定量[99mTc]Tc-DPD SPECT以改善早期风险分层。

核心结论

  • 在疑似或确诊ATTR-CM且LVEF保留(代表早期疾病阶段)的患者中,应考虑定量[99mTc]Tc-DPD SPECT以改善早期风险分层。

研究设计与样本

  • 连续纳入转诊至单中心、接受定量[99mTc]Tc-DPD SPECT/CT(可行SUVmax与SUVpeak分析)的疑似ATTR-CM患者,按基线LVEF≥50%与<50%分为2组。
  • 共纳入144例疑似ATTR-CM患者,其中LVEF≥50%组98例、LVEF<50%组46例;99例诊断为ATTR-CM(68.8%),其中LVEF≥50%组69例、LVEF<50%组30例。
  • 分析临床、实验室与超声心动图参数及主要不良心脏事件(全因死亡、持续性室性快速性心律失常、心力衰竭住院、植入心脏复律除颤器)与定量摄取值的相关性。

主要发现

  • 在疑似或确诊ATTR-CM且LVEF≥50%的患者中,心肌SUVmax至少7可预测随访21.9±13.0个月内的主要不良心脏事件(HR 2.875;95%CI 1.23-6.71;P=0.015;整体χ2=6.892,P=0.02)。
  • 在LVEF<50%的疑似或确诊ATTR-CM患者中,SUVmax无预测价值。

关键数值与推荐

  • 疑似或确诊ATTR-CM且LVEF≥50%患者中,心肌SUVmax至少7预测主要不良心脏事件的HR为2.875(95%CI 1.23-6.71;P=0.015)。
  • 该预测模型整体χ2=6.892,P=0.02。
  • 随访时间为21.9±13.0个月。

临床怎么用

  • 作者认为,对疑似或确诊ATTR-CM且LVEF保留(早期疾病阶段)的患者,应考虑定量[99mTc]Tc-DPD SPECT以改善早期风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Quantitative 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid ([99mTc]Tc-DPD) SPECT may be used for risk-stratifying patients with amyloid transthyretin-related cardiomyopathy (ATTR-CM). We aimed to analyze the predictive value of quantitative [99mTc]Tc-DPD SPECT/CT in suspected and confirmed ATTR-CM according to different disease stages. Methods: The study enrolled consecutive patients with suspected ATTR-CM who were referred to a single tertiary center and underwent quantitative [99mTc]Tc-DPD SPECT/CT allowing SUVmax and SUVpeak analysis. Patients were divided into 2 groups according to left ventricular ejection fraction (LVEF) at baseline (i.e., ≥50% and <50%). Clinical, laboratory, and echocardiographic parameters and major adverse cardiac events (i.e., all-cause death, sustained ventricular tachyarrhythmia, hospitalization for heart failure, implantation of a cardioverter defibrillator) were investigated for any correlation with quantitative uptake values. Results: In total, 144 patients with suspected ATTR-CM were included in the study (98 with LVEF ≥ 50% and 46 with LVEF < 50%), of whom 99 were diagnosed with ATTR-CM (68.8%; 69 with LVEF ≥ 50% and 30 with LVEF < 50%). A myocardial SUVmax of at least 7 was predictive of major adverse cardiac events at 21.9 ± 13.0 mo of follow-up (hazard ratio, 2.875; 95% CI, 1.23-6.71; P = 0.015) in patients with suspected or confirmed ATTR-CM (global χ2 = 6.892, P = 0.02) and an LVEF of at least 50%. SUVmax was not predictive in patients with an LVEF of less than 50% and suspected or confirmed ATTR-CM. Conclusion: In patients with suspected or confirmed ATTR-CM and preserved LVEF, representing an early disease stage, quantitative [99mTc]Tc-DPD SPECT should be considered to improve early-stage risk stratification.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Caobelli F, Gözlügöl N, Bakula A, et al. Prognostic Value of [99mTc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function. J Nucl Med. 2024. PMID: 38724281. doi:10.2967/jnumed.123.266926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。